ABSTRACT
MicroRNAs (miRNAs) are small regulatory RNAs which act by modulating the expression of target genes. In addition to their role in maintaining essential physiological functions in the cell, miRNAs can also regulate viral infections. They can do so directly by targeting RNAs of viral origin or indirectly by targeting host mRNAs, and this can result in a positive or negative outcome for the virus. Here, we performed a fluorescence-based miRNA genome-wide screen in order to identify cellular miRNAs involved in the regulation of arbovirus infection in human cells. We identified 16 miRNAs showing a positive effect on Sindbis virus (SINV) expressing green fluorescent protein (GFP), among which were a number of neuron-specific ones such as miR-124. We confirmed that overexpression of miR-124 increases both SINV structural protein translation and viral production and that this effect is mediated by its seed sequence. We further demonstrated that the SINV genome possesses a binding site for miR-124. Both inhibition of miR-124 and silent mutations to disrupt this binding site in the viral RNA abolished positive regulation. We also proved that miR-124 inhibition reduces SINV infection in human differentiated neuronal cells. Finally, we showed that the proviral effect of miR-124 is conserved in other alphaviruses, as its inhibition reduces chikungunya virus (CHIKV) production in human cells. Altogether, our work expands the panel of positive regulation of the viral cycle by direct binding of host miRNAs to the viral RNA and provides new insights into the role of cellular miRNAs as regulators of alphavirus infection.IMPORTANCE Arthropod-borne (arbo) viruses are part of a class of pathogens that are transmitted to their final hosts by insects. Because of climate change, the habitat of some of these insects, such as mosquitoes, is shifting, thereby facilitating the emergence of viral epidemics. Among the pathologies associated with arbovirus infection, neurological diseases such as meningitis and encephalitis represent a significant health burden. Using a genome-wide miRNA screen, we identified neuronal miR-124 as a positive regulator of the Sindbis and chikungunya alphaviruses. We also showed that this effect was in part direct, thereby opening novel avenues to treat alphavirus infections.
Subject(s)
Alphavirus Infections/genetics , Alphavirus/genetics , MicroRNAs/genetics , Alphavirus/metabolism , Alphavirus Infections/diagnosis , Cell Line , Chikungunya Fever/genetics , Chikungunya virus/genetics , Fluorescence , High-Throughput Screening Assays/methods , Host-Pathogen Interactions , Humans , MicroRNAs/metabolism , Neurons/metabolism , RNA, Viral/metabolism , Sindbis Virus/genetics , Virus ReplicationABSTRACT
Chikungunya virus (CHIKV) is an arthritogenic arbovirus of the Alphavirus genus, which has infected millions of people after its re-emergence in the last decade. In this study, a BHK cell line containing a stable CHIKV replicon with a luciferase reporter was used in a high-throughput platform to screen approximately 3000 compounds. Following initial validation, 25 compounds were chosen as primary hits for secondary validation with wild type and reporter CHIKV infection, which identified three promising compounds. Abamectin (EC50 = 1.5 µM) and ivermectin (EC50 = 0.6 µM) are fermentation products generated by a soil dwelling actinomycete, Streptomyces avermitilis, whereas berberine (EC50 = 1.8 µM) is a plant-derived isoquinoline alkaloid. They inhibited CHIKV replication in a dose-dependent manner and had broad antiviral activity against other alphaviruses--Semliki Forest virus and Sindbis virus. Abamectin and ivermectin were also active against yellow fever virus, a flavivirus. These compounds caused reduced synthesis of CHIKV genomic and antigenomic viral RNA as well as downregulation of viral protein expression. Time of addition experiments also suggested that they act on the replication phase of the viral infectious cycle.
Subject(s)
Alphavirus/drug effects , Antiviral Agents/pharmacology , Chikungunya Fever/drug therapy , Chikungunya virus/drug effects , Alphavirus/physiology , Animals , Berberine/pharmacology , Cell Line , Cell Line, Tumor , Chikungunya Fever/virology , Chikungunya virus/physiology , Cricetinae , DNA, Viral/antagonists & inhibitors , DNA, Viral/biosynthesis , DNA, Viral/drug effects , Flavivirus/drug effects , Humans , Ivermectin/analogs & derivatives , Ivermectin/pharmacology , RNA, Viral/antagonists & inhibitors , RNA, Viral/biosynthesis , RNA, Viral/drug effects , RNA, Viral/genetics , Replicon/drug effects , Viral Proteins/antagonists & inhibitors , Viral Proteins/biosynthesis , Viral Proteins/drug effects , Virus Replication/drug effects , Yellow fever virus/drug effectsABSTRACT
UNLABELLED: Small RNAs play a critical role in host-pathogen interaction. Indeed, small RNA-mediated silencing or RNA interference (RNAi) is one of the earliest forms of antiviral immunity. Although it represents the main defense system against viruses in many organisms, the antiviral role of RNAi has not been clearly proven in higher vertebrates. However, it is well established that their response to viral infection relies on the recognition of viral RNAs by host pattern recognition receptors (PRRs) to trigger activation of the interferon pathway. In the present work, we report the existence of a novel small noncoding RNA population produced in mammalian cells upon RNA virus infection. Using Sindbis virus (SINV) as a prototypic arbovirus model, we profiled the small RNA population of infected cells in both human and African green monkey cell lines. Here, we provide evidence for the presence of discrete small RNAs of viral origin that are not associated with the RNA-induced silencing complex (RISC), that are highly expressed and detected by Northern blot analysis, and that accumulate as 21- to 28-nucleotide (nt) species during infection. We report that the cellular antiviral endoribonuclease RNase L cleaves the viral genome, producing in turn the small RNAs. Surprisingly, we uncovered the presence of a modification on the 3'-end nucleotide of SINV-derived viral small RNAs (SvsRNAs) that might be at the origin of their stability. Altogether, our findings show that stable modified small viral RNAs could represent a novel way to modulate host-virus interaction upon SINV infection. IMPORTANCE: In a continuous arms race, viruses have to deal with host antiviral responses in order to successfully establish an infection. In mammalian cells, the host defense mechanism relies on the recognition of viral RNAs, resulting in the activation of type I interferons (IFNs). In turn, the expression of many interferon-stimulated genes (ISGs) is induced to inhibit viral replication. Here we report that the cytoplasmic, interferon-induced, cellular endoribonuclease RNase L is involved in the accumulation of a novel small RNA population of viral origin. These small RNAs are produced upon SINV infection of mammalian cells and are stabilized by a 3'-end modification. Altogether, our findings indicate that in our system RNA silencing is not active against Sindbis virus (SINV) and might open the way to a better understanding of the antiviral response mediated by a novel class of small RNAs.
Subject(s)
Endoribonucleases/metabolism , Host-Pathogen Interactions , RNA, Small Untranslated/metabolism , RNA, Viral/metabolism , Sindbis Virus/physiology , Animals , Cell Line , Chlorocebus aethiops , Gene Expression Profiling , Humans , RNA Processing, Post-TranscriptionalABSTRACT
Hepatitis C virus (HCV) encodes for several proteins that can interfere with host cell signaling and antiviral response. Previously, serine protease NS3/4A was shown to block host cell interferon (IFN) production by proteolytic cleavage of MAVS and TRIF, the adaptor molecules of the RIG-I and TLR3 signaling pathways, respectively. This study shows that another HCV protease, NS2 can interfere efficiently with cytokine gene expression. NS2 and its proteolytically inactive mutant forms were able to inhibit type I and type III IFN, CCL5 and CXCL10 gene promoters activated by Sendai virus infection. However, the CXCL8 gene promoter was not inhibited by NS2. In addition, constitutively active RIG-I (ΔRIG-I), MAVS, TRIF, IKKε, and TBK1-induced activation of IFN-ß promoter was inhibited by NS2. Cotransfection experiments with IKKε or TBK1 together with interferon regulatory factor 3 (IRF3) and HCV expression constructs revealed that NS2 in a dose-dependent manner inhibited IKKε and especially TBK1-induced IRF3 phosphorylation. GST pull-down experiments with GST-NS2 and in vitro-translated and cell-expressed IKKε and TBK1 demonstrated direct physical interactions of the kinases with NS2. Further evidence that the IKKε/TBK1 kinase complex is the target for NS2 was obtained from the observation that the constitutively active form of IRF3 (IRF3-5D) activated readily IFN-ß promoter in the presence of NS2. The present study identified HCV NS2 as a potent interferon antagonist, and describes an explanation of how NS2 downregulates the major signaling pathways involved in the development of host innate antiviral responses.
Subject(s)
Hepacivirus/pathogenicity , Host-Pathogen Interactions , I-kappa B Kinase/antagonists & inhibitors , Protein Serine-Threonine Kinases/antagonists & inhibitors , Viral Nonstructural Proteins/metabolism , Centrifugation , Cytokines/antagonists & inhibitors , Hepacivirus/immunology , Humans , I-kappa B Kinase/immunology , Protein Binding , Protein Interaction Mapping , Protein Serine-Threonine Kinases/immunology , Viral Nonstructural Proteins/immunologyABSTRACT
Hepatitis C virus multiplies efficiently in the body and causes a chronic infection. The current treatment with pegylated interferon and ribavirin is effective only in some patients. The viral genome codes for no more than ten proteins, several of which are, however, proving to be suitable targets for small-molecular inhibitors. Two protease inhibitors have been approved for therapeutic use. Preliminary results anticipate good efficiency for the new drugs either combined with previous therapy or by using combinations of the new inhibitors.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Protease Inhibitors/therapeutic use , Ribavirin/therapeutic use , Humans , Interferon alpha-2 , Recombinant Proteins/therapeutic useABSTRACT
Influenza A viruses (IAVs) infect humans and cause significant morbidity and mortality. Different treatment options have been developed; however, these were insufficient during recent IAV outbreaks. Here, we conducted a targeted chemical screen in human nonmalignant cells to validate known and search for novel host-directed antivirals. The screen validated saliphenylhalamide (SaliPhe) and identified two novel anti-IAV agents, obatoclax and gemcitabine. Further experiments demonstrated that Mcl-1 (target of obatoclax) provides a novel host target for IAV treatment. Moreover, we showed that obatoclax and SaliPhe inhibited IAV uptake and gemcitabine suppressed viral RNA transcription and replication. These compounds possess broad spectrum antiviral activity, although their antiviral efficacies were virus-, cell type-, and species-specific. Altogether, our results suggest that phase II obatoclax, investigational SaliPhe, and FDA/EMEA-approved gemcitabine represent potent antiviral agents.
Subject(s)
Amides/pharmacology , Antiviral Agents/pharmacology , Deoxycytidine/analogs & derivatives , Influenza A Virus, H3N2 Subtype/drug effects , Influenza A Virus, H3N2 Subtype/physiology , Influenza, Human/drug therapy , Pyrroles/pharmacology , Salicylates/pharmacology , Animals , Chlorocebus aethiops , Deoxycytidine/pharmacology , Dogs , Humans , Indoles , Influenza, Human/metabolism , Myeloid Cell Leukemia Sequence 1 Protein , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/metabolism , RNA, Viral/biosynthesis , Vero Cells , Virus Replication , GemcitabineABSTRACT
The hepatitis C virus (HCV) non-structural (NS) 3/4A protein complex inhibits the retinoic acid inducible gene I (RIG-I) pathway by proteolytically cleaving mitochondria-associated CARD-containing adaptor protein Cardif, and this leads to reduced production of beta interferon (IFN-beta). This study examined the expression of CCL5 (regulated upon activation, normal T-cell expressed and secreted, or RANTES), CXCL8 (interleukin 8) and CXCL10 (IFN-gamma-activated protein 10, or IP-10) chemokine genes in osteosarcoma cell lines that inducibly expressed NS3/4A, NS4B, core-E1-E2-p7 and the entire HCV polyprotein. Sendai virus (SeV)-induced production of IFN-beta, CCL5, CXCL8 and CXCL10 was downregulated by the NS3/4A protein complex and by the full-length HCV polyprotein. Expression of NS3/4A and the HCV polyprotein reduced the binding of interferon regulatory factors (IRFs) 1 and 3 and, to a lesser extent, nuclear factor (NF)-kappaB (p65/p50) to their respective binding elements on the CXCL10 promoter during SeV infection. Furthermore, binding of IRF1 and IRF3 to the interferon-stimulated response element-like element, and of c-Jun and phosphorylated c-Jun to the activator protein 1 element of the CXCL8 promoter, was reduced when NS3/4A and the HCV polyprotein were expressed. In cell lines expressing NS3/4A and the HCV polyprotein, the subcellular localization of mitochondria was changed, and this was kinetically associated with the partial degradation of endogenous Cardif. These results indicate that NS3/4A alone or as part of the HCV polyprotein disturbs the expression of IRF1- and IRF3-regulated genes, as well as affecting mitogen-activated protein kinase kinase- and NF-kappaB-regulated genes.
Subject(s)
Chemokines/metabolism , Gene Expression Regulation, Viral/drug effects , Hepacivirus/chemistry , Hepatitis C/genetics , Promoter Regions, Genetic/drug effects , Chemokines/genetics , Down-Regulation , Hepacivirus/genetics , Hepatitis C/metabolism , Hepatitis C/virology , Mitochondria/physiology , Polyproteins/metabolism , Promoter Regions, Genetic/physiology , Signal Transduction/drug effects , Tumor Cells, Cultured , Viral Nonstructural ProteinsABSTRACT
The S RNA genome segment of hantaviruses carried by Arvicolinae and Sigmodontinae rodents encodes the nucleocapsid (N) protein and has an overlapping (+1) open reading frame (ORF) for a putative nonstructural protein (NSs). The aim of this study was to determine whether the ORF is functional. A protein corresponding to the predicted size of Tula virus (TULV) NSs was detected using coupled in vitro transcription and translation from a cloned S segment cDNA, and a protein corresponding to the predicted size of Puumala virus (PUUV) NSs was detected in infected cells by Western blotting with an anti-peptide serum. The activities of the interferon beta (IFN-beta) promoter, and nuclear factor kappa B (NF-kappaB)- and interferon regulatory factor-3 (IRF-3) responsive promoters, were inhibited in COS-7 cells transiently expressing TULV or PUUV NSs. Also IFN-beta mRNA levels in IFN-competent MRC5 cells either infected with TULV or transiently expressing NSs were decreased. These data demonstrate that Tula and Puumala hantaviruses have a functional NSs ORF. The findings may explain why the NSs ORF has been preserved in the genome of most hantaviruses during their long evolution and why hantavirus-infected cells secrete relatively low levels of IFNs.
Subject(s)
Hantavirus Infections/metabolism , Interferon-beta/genetics , Nucleocapsid Proteins/genetics , Open Reading Frames/physiology , Orthohantavirus/genetics , Promoter Regions, Genetic , Viral Nonstructural Proteins/physiology , Amino Acid Sequence , Animals , COS Cells , Cell Line , Chlorocebus aethiops , Down-Regulation , Hantavirus Infections/virology , Hemorrhagic Fever with Renal Syndrome/metabolism , Hemorrhagic Fever with Renal Syndrome/virology , Humans , Interferon Regulatory Factor-3/biosynthesis , Interferon Regulatory Factor-3/genetics , Interferon-beta/biosynthesis , Molecular Sequence Data , NF-kappa B/biosynthesis , NF-kappa B/genetics , Puumala virus/genetics , Sequence AlignmentABSTRACT
BACKGROUND: Hepatitis C virus (HCV) encodes several proteins that interfere with the host cell antiviral response. Previously, the serine protease NS3/4A was shown to inhibit IFN-beta gene expression by blocking dsRNA-activated retinoic acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3)-mediated signaling pathways. RESULTS: In the present work, we systematically studied the effect of all HCV proteins on IFN gene expression. NS2 and NS3/4A inhibited IFN gene activation. NS3/4A inhibited the Sendai virus-induced expression of multiple IFN (IFN-alpha, IFN-beta and IFN-lambda1/IL-29) and chemokine (CCL5, CXCL8 and CXCL10) gene promoters. NS2 and NS3/4A, but not its proteolytically inactive form NS3/4A-S139A, were found to inhibit promoter activity induced by RIG-I or its adaptor protein Cardif (or IPS-1/MAVS/VISA). Both endogenous and transfected Cardif were proteolytically cleaved by NS3/4A but not by NS2 indicating different mechanisms of inhibition of host cell cytokine production by these HCV encoded proteases. Cardif also strongly colocalized with NS3/4A at the mitochondrial membrane, implicating the mitochondrial membrane as the site for proteolytic cleavage. In many experimental systems, IFN priming dramatically enhances RNA virus-induced IFN gene expression; pretreatment of HEK293 cells with IFN-alpha strongly enhanced RIG-I expression, but failed to protect Cardif from NS3/4A-mediated cleavage and failed to restore Sendai virus-induced IFN-beta gene expression. CONCLUSION: HCV NS2 and NS3/4A proteins were identified as potent inhibitors of cytokine gene expression suggesting an important role for HCV proteases in counteracting host cell antiviral response.
Subject(s)
Gene Expression Regulation , Hepacivirus/chemistry , Hepacivirus/immunology , Interferon-beta/genetics , Viral Nonstructural Proteins/metabolism , Adaptor Proteins, Signal Transducing/analysis , Adaptor Proteins, Signal Transducing/metabolism , Cell Line , Cytokines/genetics , DEAD Box Protein 58 , DEAD-box RNA Helicases , Gene Expression/drug effects , Humans , Interferon-alpha/pharmacology , Mitochondrial Membranes/chemistry , Promoter Regions, Genetic , RNA Helicases/genetics , RNA Helicases/immunology , RNA Helicases/metabolism , Receptors, Immunologic , Signal Transduction , Toll-Like Receptor 3/genetics , Toll-Like Receptor 3/immunology , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/immunology , Transcriptional Activation , Tumor Necrosis Factor-alpha/pharmacology , Viral Nonstructural Proteins/analysis , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/immunologyABSTRACT
The structure of the nucleocapsid protein of bunyaviruses has not been defined. Earlier we have shown that Tula hantavirus N protein oligomerization is dependent on the C-terminal domains. Of them, the helix-loop-helix motif was found to be an essential structure. Computer modeling predicted that oligomerization occurs via helix protrusions, and the shared hydrophobic space formed by amino acids residues 380-IILLF-384 in the first helix and 413-LI-414 in the second helix is responsible for stabilizing the interaction. The model was validated by two approaches. First, analysis of the oligomerization capacity of the N protein mutants performed with the mammalian two-hybrid system showed that both preservation of the helix structure and formation of the shared hydrophobic space are crucial for the interaction. Second, oligomerization was shown to be a prerequisite for the granular pattern of transiently expressed N protein in transfected cells. N protein trimerization was supported by three-dimensional reconstruction of the N protein by electron microscopy after negative staining. Finally, we discuss how N protein trimerization could occur.
Subject(s)
Nucleocapsid Proteins/chemistry , Nucleocapsid Proteins/metabolism , Orthohantavirus/metabolism , Amino Acid Sequence , Animals , COS Cells , Chlorocebus aethiops , Dimerization , Orthohantavirus/chemistry , Orthohantavirus/genetics , HeLa Cells , Helix-Loop-Helix Motifs , Humans , Models, Molecular , Molecular Sequence Data , Nucleocapsid Proteins/genetics , Protein Structure, Secondary , Two-Hybrid System TechniquesABSTRACT
Hantavirus nucleocapsid (N) protein has been suggested to form homodimers and homotrimers that are further integrated into the nucleocapsid filaments around the viral RNA. Here we report detailed mapping of the regions involved in the homotypic N protein interactions in Tula hantavirus (TULV). Peptide scan screening was used to define the interaction regions, and the mammalian two-hybrid assay was used for the functional analysis of N protein mutants. To study linear regions responsible for N protein interaction(s), we used peptide scanning in which N peptides synthesized on membranes recognize recombinant TULV N protein. The data showed that the N protein bound to membrane-bound peptides comprising amino acids 13 to 30 and 41 to 57 in the N-terminal part and 340 to 379, 391 to 407, and 410 to 419 in the C-terminal part of the molecule. Further mapping of the interaction regions by alanine scanning indicated the importance of basic amino acids along the N protein and especially asparagine-394, histidine-395, and phenyalanine-396 in forming the binding interface. Analysis of truncated mutants in the mammalian two-hybrid assay showed that N-terminal amino acids 1 to 43 are involved in and C-terminal amino acids 393 to 398 (VNHFHL) are absolutely crucial for the homotypic interactions. Furthermore, our data suggested a tail-to-tail and head-to-head binding scheme for the N proteins.
Subject(s)
Capsid Proteins/chemistry , Viral Core Proteins/chemistry , Amino Acid Sequence , Animals , COS Cells , Molecular Sequence Data , Two-Hybrid System TechniquesABSTRACT
To find cellular binding counterparts for the nucleocapsid protein (N) of Tula hantavirus (TULV), two cDNA libraries were screened using yeast two-hybrid systems based on LexA and Gal4 transcription factors. Five cDNA clones encoding SUMO-1 (Small Ubiquitin-related MOdifier, also known as sentrin) were selected in the LexA system. Confocal microscopy revealed that, in infected cells, TULV N protein and SUMO-1 colocalize at the perinuclear area providing further evidence for interaction between the two proteins. Neither endogenous nor transiently expressed SUMO-1 was found to be covalently linked to the N protein. Additional evidence that the interaction is non-covalent was obtained in immunoprecipitation experiments: N protein-specific antibodies precipitated SUMO-1 from TULV-infected Vero E6 cell lysate. By using a pepscan assay, two basic amino acid stretches in the N-terminal part of SUMO-1 were shown to be involved in the interaction.
Subject(s)
Nucleocapsid Proteins/metabolism , Orthohantavirus/metabolism , SUMO-1 Protein/metabolism , Amino Acid Sequence , Animals , Binding Sites/genetics , Chlorocebus aethiops , DNA, Complementary/genetics , Orthohantavirus/genetics , Microscopy, Confocal , Molecular Sequence Data , Nucleocapsid Proteins/genetics , Peptide Fragments/genetics , Peptide Fragments/metabolism , Protein Binding , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , SUMO-1 Protein/genetics , Transfection , Two-Hybrid System Techniques , Vero CellsABSTRACT
Intermolecular interactions of Tula hantavirus N (nucleocapsid) protein were detected in the yeast two-hybrid system, prompting further attempts to study this phenomenon. Using chemical cross-linking and immunoblotting it was shown that the N protein from purified virus and from infected cell lysates as well as recombinant protein produced in a baculovirus expression system are capable of forming dimers, trimers and multimers, thus confirming the capacity of the protein molecules to interact with each other. An ELISA format was developed in which molecules of the recombinant N protein were shown to associate non-covalently, via electrostatic interactions. Divalent cations (Ca(2+), Mn(2+), Mg(2+), Ba(2+)) enhanced the process 3- to 8-fold suggesting that adequate folding of the N protein is crucial for the association. Based on these data a model for hantavirus nucleocapsid assembly is proposed, in which N molecules first trimerize around the viral RNA molecule, and then the trimers gradually assemble forming longer multimers.